These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 25546091

  • 21. Fetal hemoglobin and alpha thalassemia modulate the phenotypic expression of HbSD-Punjab.
    Patel DK, Purohit P, Dehury S, Das P, Dutta A, Meher S, Patel S, Bag S, Mashon RS, Das K.
    Int J Lab Hematol; 2014 Aug; 36(4):444-50. PubMed ID: 24245819
    [Abstract] [Full Text] [Related]

  • 22. Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E-β-thalassemia): a single center study from Eastern India.
    Bohara VV, Ray S, Chakrabarti P, Ray SS, Nath UK, Chaudhuri U.
    Hemoglobin; 2014 Aug; 38(1):44-8. PubMed ID: 24144212
    [Abstract] [Full Text] [Related]

  • 23. An age dependent response to hydroxyurea in pediatric sickle cell anemia patients with alpha thalassemia trait.
    Figueiredo L, Morrone K, Wei C, Ireland K, Cohen HW, Driscoll C, Manwani D.
    Blood Cells Mol Dis; 2017 Jul; 66():19-23. PubMed ID: 28783617
    [Abstract] [Full Text] [Related]

  • 24. Efficacy of hydroxyurea (HU) in reduction of pack red cell (PRC) transfusion requirement among children having beta-thalassemia major: Karachi HU trial (KHUT).
    Ansari SH, Shamsi TS, Siddiqui FJ, Irfan M, Perveen K, Farzana T, Panjwani VK, Yousuf A, Mehboob T.
    J Pediatr Hematol Oncol; 2007 Nov; 29(11):743-6. PubMed ID: 17984691
    [Abstract] [Full Text] [Related]

  • 25. Hydroxyurea-induced hematological response in transfusion-independent beta-thalassemia intermedia: case series and review of literature.
    Ehsani MA, Hedayati-Asl AA, Bagheri A, Zeinali S, Rashidi A.
    Pediatr Hematol Oncol; 2009 Nov; 26(8):560-5. PubMed ID: 19954365
    [Abstract] [Full Text] [Related]

  • 26. Hydroxyurea therapy in 49 patients with major beta-thalassemia.
    Zamani F, Shakeri R, Eslami SM, Razavi SM, Basi A.
    Arch Iran Med; 2009 May; 12(3):295-7. PubMed ID: 19400608
    [Abstract] [Full Text] [Related]

  • 27. Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults.
    Charache S.
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):15-21. PubMed ID: 9317197
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Cost analysis of acute care resource utilization among individuals with sickle cell disease in a middle-income country.
    Lobo C, Moura P, Fidlarczyk D, Duran J, Barbosa R, Oliveira T, do Nascimento EM, Bhakta N, Hankins JS.
    BMC Health Serv Res; 2022 Jan 08; 22(1):42. PubMed ID: 34998394
    [Abstract] [Full Text] [Related]

  • 30. Quantification of HBG mRNA in primary erythroid cultures: prediction of the response to hydroxyurea in sickle cell and beta-thalassemia.
    Pecoraro A, Rigano P, Troia A, Calzolari R, Scazzone C, Maggio A, Steinberg MH, Di Marzo R.
    Eur J Haematol; 2014 Jan 08; 92(1):66-72. PubMed ID: 24112139
    [Abstract] [Full Text] [Related]

  • 31. Cerebrovascular events in sickle cell-beta thalassemia treated with hydroxyurea: a single center prospective survey in adult Italians.
    Rigano P, Pecoraro A, Calvaruso G, Steinberg MH, Iannello S, Maggio A.
    Am J Hematol; 2013 Nov 08; 88(11):E261-4. PubMed ID: 23828131
    [Abstract] [Full Text] [Related]

  • 32. [Effect of hydroxyurea on hemoglobin S].
    Torres AF, Eberle SE, Sciuccati G, Bonduel M.
    Medicina (B Aires); 2003 Nov 08; 63(2):140-2. PubMed ID: 12793083
    [Abstract] [Full Text] [Related]

  • 33. Concordant fetal hemoglobin response to hydroxyurea in siblings with sickle cell disease.
    Steinberg MH, Voskaridou E, Kutlar A, Loukopoulos D, Koshy M, Ballas SK, Castro O, Barton F.
    Am J Hematol; 2003 Feb 08; 72(2):121-6. PubMed ID: 12555216
    [Abstract] [Full Text] [Related]

  • 34. Response to hydroxyurea in beta thalassemia major and intermedia: experience in western India.
    Italia KY, Jijina FJ, Merchant R, Panjwani S, Nadkarni AH, Sawant PM, Nair SB, Ghosh K, Colah RB.
    Clin Chim Acta; 2009 Sep 08; 407(1-2):10-5. PubMed ID: 19545554
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Advances in the use of hydroxyurea.
    Ware RE, Aygun B.
    Hematology Am Soc Hematol Educ Program; 2009 Sep 08; ():62-9. PubMed ID: 20008183
    [Abstract] [Full Text] [Related]

  • 37. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia.
    Karimi M, Mohammadi F, Behmanesh F, Samani SM, Borzouee M, Amoozgar H, Haghpanah S.
    Eur J Haematol; 2010 Jan 01; 84(1):52-8. PubMed ID: 19799627
    [Abstract] [Full Text] [Related]

  • 38. Report on patients with non transfusion-dependent β-thalassemia major being treated with hydroxyurea attending the Thalassemia Research Center, Sari, Mazandaran Province, Islamic Republic of Iran in 2013.
    Kosaryan M, Karami H, Zafari M, Yaghobi N.
    Hemoglobin; 2014 Jan 01; 38(2):115-8. PubMed ID: 24471558
    [Abstract] [Full Text] [Related]

  • 39. Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA).
    Sumoza A, de Bisotti R, Sumoza D, Fairbanks V.
    Am J Hematol; 2002 Nov 01; 71(3):161-5. PubMed ID: 12410569
    [Abstract] [Full Text] [Related]

  • 40. Response to hydroxyurea therapy in beta-thalassemia.
    Koren A, Levin C, Dgany O, Kransnov T, Elhasid R, Zalman L, Palmor H, Tamary H.
    Am J Hematol; 2008 May 01; 83(5):366-70. PubMed ID: 18181203
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.